Significant Accounting Estimates And Judgements (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
Sep. 30, 2024	Dec. 31, 2025	Dec. 31, 2024
Disclosure of notes and other explanatory information [Abstract]
Reversal of impairment expense	$ 57.1
Reversal of impairment (Note 10)		$ (218.8)	$ (57.1)
Gain on sale of assets (Note 7)		$ 231.0	$ 0.0

The gains (losses) recognised in association with the loss of control over a subsidiary, which are attributable to the former controlling interest.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2025-01-01
-Paragraph 19
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_19&doctype=Standard
-URIDate 2025-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 81
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_81&doctype=Standard
-URIDate 2025-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 81
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_81&doctype=Standard
-URIDate 2025-03-27

Name:	ifrs-full_GainsLossesRecognisedWhenControlInSubsidiaryIsLost
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration